Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Viracta Therapeutics (Nasdaq: VIRX), a precision oncology firm, announced its upcoming presentation at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Viracta Therapeutics (Nasdaq: VIRX), a precision oncology firm, announced its upcoming presentation at the H.C. Wainwright BIOCONNECT Virtual Conference scheduled for January 10, 2022, starting at 7:00 a.m. ET. The pre-recorded webcast will be accessible on-demand at the Viracta website and will be archived for 90 days.
Viracta is focusing on virus-associated malignancies with its investigational drug, nanatinostat, currently in pivotal trials for EBV-positive lymphoma and other related cancers.
Details
News Market Reaction – VIRX
The recorded move for VIRX in the trading session of this news was -6.39%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the H.C. Wainwright BIOCONNECT Virtual Conference.
The pre-recorded webcast will be available for on-demand viewing beginning Monday, January 10, 2022, at 7:00 a.m. ET on the Investors section of the Viracta website under "Events and Webcasts" at https://viracta.investorroom.com/events-and-webcasts. The webcast will be archived for 90 days.
About Viracta Therapeutics, Inc.
Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy, Nana-Val, in a pivotal Phase 2 clinical trial for EBV-positive (EBV+) lymphoma and a Phase 1b/2 trial in patients with EBV+ nasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.
For additional information please visit www.viracta.com.
Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-hc-wainwright-bioconnect-virtual-conference-301453062.html
SOURCE Viracta Therapeutics, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.